MYOKARDIA, INC. (NASDAQ:MYOK) Files An 8-K Regulation FD Disclosure
Item7.01
| Regulation FD Disclosure |
MyoKardia, Inc. (the Company) is furnishing a corporate
presentation, attached as Exhibit 99.1 to this Current Report on
Form 8-K, which the Company intends to use from time to time in
meetings with investors and others beginning on March6, 2017. The
corporate presentation will also be available on the Companys
website at http://investors.myokardia.com.
The information in this Item 7.01 and Exhibit 99.1 attached
hereto is intended to be furnished and shall not be deemed filed
for purposes of Section18 of the Securities Exchange Act of 1934,
as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.
| Item9.01 | Financial Statements and Exhibits |
| (d) | Exhibits. |
The following exhibit relating to Item 7.01 shall be deemed
furnished, and not filed:
|
Exhibit No. |
Description |
|
| 99.1 | MyoKardia, Inc. Corporate Presentation (March 2017) |
About MYOKARDIA, INC. (NASDAQ:MYOK)
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics. Its pipeline includes over four therapeutic programs for the chronic treatment of over two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Its lead product candidate, MYK-461, is an orally-administered small molecule that reduces cardiac muscle contractility leading to HCM. In preclinical models of HCM, MYK-461 has been shown to prevent and reverse disease progression and to reduce left ventricular outflow tract obstruction. It is evaluating MYK-461 in over three Phase I clinical trials, including approximately two single ascending dose (SAD) trials and over one multiple ascending dose (MAD) trial. MYOKARDIA, INC. (NASDAQ:MYOK) Recent Trading Information
MYOKARDIA, INC. (NASDAQ:MYOK) closed its last trading session down -0.15 at 12.55 with 45,448 shares trading hands.
